^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    minocycline

    Associations
    News

    Trials

    Company:
    Generic mfg.
    Drug class:
    Immunomodulator, Protein synthesis inhibitor, IL-1α inhibitor, IL-6 modulator
    Related drugs:
    Associations
    News

    Trials

    Apply
    Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib (COCOON) (NCT06120140)
    Phase 2
    Janssen Research & Development, LLC
    Recruiting
    Last update posted :
    02/14/2025
    Initiation :
    02/16/2024
    Primary completion :
    11/07/2025
    Completion :
    03/31/2026
    EGFR
    |
    EGFR L858R • EGFR exon 19 deletion
    |
    Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib) • amivantamab SC (Ami-LC) • minocycline